Introduction 42
Lipopolysaccharide (LPS) is the major component of the outer wall of gram-43 negative bacteria. It activates macrophages, neutrophils, dendritic, and other cells that 44 induce inflammation, oxidative stress and endothelial damage (6). Exposure to LPS 45 leads to endothelial barrier dysfunction, increased endothelial permeability, acute lung 46 injury and acute respiratory distress syndrome (1). We have recently reported that heat 47 shock protein 90 (Hsp90) is an important positive regulator of these effects of LPS and 48 that inhibitors of Hsp90 prevent and repair the LPS-induced cellular damage, both in 49 vitro and in vivo (3, 26, 59) . 50
Hsp90 is a highly conserved cellular chaperone and one of the most abundant 51 proteins in eukaryotic cells (27) . It represents 1-2% of total cellular proteins and 52 participates in the stabilization and activation of more than 200 "client" proteins (61) . 53
Hsp90 forms multichaperone complexes with a variety of cochaperones and 54 proinflammatory client proteins. These complexes cycle between an open and a closed 55 conformation of the dimeric Hsp90. Hsp90 inhibitors, such as 17-allyl-amino-56 demethoxy-geldanamycin (17-AAG), lock the complex in the open state leading to client 57 protein deactivation, destabilization, and proteasomal degradation (52). 58 p53 serves as an Hsp90 client protein able to regulate major metabolic pathways 59 and cytokines which are required for cellular growth and defense (34, 51) . Hsp90 binds 60 to a folded, native-like conformation of p53 in vitro with micromolar affinity. The DNA-61 binding domain of p53 and the middle and carboxy-terminal domains of Hsp90 are 62 responsible for this interaction, which is essential to stabilize p53 at physiological 63 values +/-SEM (standard error of mean). Student's t test, one-way or two-way ANOVA 144
with Bonferroni post-hoc test was performed to determine statistically significant 145 differences among groups. A value of P<0.05 was considered significant. GraphPad 146 Prism 4 (version 4.03, Graph Pad Software) was used for data analysis. n represents 147 the number of experimental repeats. 148 149 p53 inhibition reduces endothelial barrier integrity. HLMVEC were seeded on gold 151 electrode arrays and were exposed to DMSO (vehicle), 25μM or 50μM of the p53 152 expression inhibitor, pifithrin. Figure 1A shows that pifithrin induced a concentration-153 dependent decrease in p53 expression. Furthermore, DMSO-treated cells maintained 154 constant transendothelial resistance (TER) values, whereas cells exposed to 50μM 155 pifithrin exhibited a significant reduction in TER values (Fig. 1B) . 156
Effects of p53 inhibition by pifithrin on LPS-induced endothelial barrier 157
dysfunction. HLMVEC were seeded on gold electrode arrays and were exposed to 158 either 10% DMSO (vehicle) 
or 50μM pifithrin before a 4 hour treatment with PBS 159 (vehicle) or LPS (1EU/ml). PBS-treated cells maintained constant TER values, in 160
contrast to the pifithrin-treated cells which exhibited reduced transendothelial resistance 161 (Fig. 1C) . LPS profoundly reduced TER in both vehicle and pifithrin-treated cells, 162 however the LPS-induced decrease in TER values was far greater in pifithrin-treated 163 cells (Fig. 1C) . 164
Effects of p53 induction by Nutlin on endothelial barrier dysfunction. Figure 1D , 165 upper right panel, demonstrates that p53 expression increased significantly in cells 166 treated for 4h with 10μM nutlin. In additional experiments, HLMVEC were seeded on 167 gold electrode arrays and were exposed to DMSO (vehicle) or 10μM nutlin for 4 hours 168 before PBS (vehicle) or LPS (1EU/ml) treatment. As shown in figure 1D , cells treated 169 with PBS maintained stable TER values (Fig. 1E ). The addition of LPS significantly 170 reduced TER in vehicle-treated cells, but not in cells pretreated with the p53 inducer, 171 nutlin. 172 right panel, demonstrates that p53 expression was significantly reduced by p53 174 silencing with a specific siRNA. In additional experiments, HLMVEC were seeded on 175 gold electrode arrays and were exposed to control siRNA or p53 siRNA (t=0). As shown 176 in figure 1E , cells treated with control siRNA maintained stable TER values. On the 177 other hand, cells subjected to p53 siRNA treatment exhibited significantly reduced TER 178
values. 179
Suppression of p53 expression by LPS. HLMVEC were exposed to either vehicle 180 (PBS) or LPS (1EU/ml) for 2 hours. Cells exposed to LPS exhibited decreased p53 181 expression compared to the vehicle-treated cells ( Fig. 2A) . 182 Induction of p53 expression by 17-AAG. HLMVEC were treated with either vehicle 183 (DMSO) or the Hsp90 inhibitor, 17-AAG (1μM) for 4 or 16 hours. As shown in figure 2B , 184 17-AAG treatment for either time-period significantly increased p53 expression 185 compared to vehicle-treated cells. 186 Suppression of p21 expression by LPS. HLMVEC were exposed to either vehicle 187 (PBS) or LPS (1EU/ml) for 2 hours. Cells exposed to LPS demonstrated decreased 188 expression of the p53 target, p21, compared to vehicle-treated cells (Fig. 2C) . 189 (Fig. 3A) . In additional studies, mice received either vehicle or 196 the Hsp90 inhibitor, AUY922 (AUY) intraperitoneally 24 hours after vehicle or LPS 197 (intratracheally) and tissues were analyzed 72 hours after LPS. As shown in Figure 3 , 198 lungs from LPS-treated mice exhibited significantly lower expression of p53, even after 199 72h. AUY reversed the LPS-induced p53 downregulation (Fig. 3B ) and induced p21 200 expression (Fig. 3C) HLMVEC. HLMVEC were exposed to either vehicle, LPS (1EU/ml) for 2 hours or 17-209 AAG for 8 hours. LPS reduced and 17-AAG increased p53 expression (Fig. 4, upper  210 panel). Immunoblotting of samples which were immunoprecipitated with p53 antibody 211
showed that LPS-treated cells contained less of the Hsp90/p53 complex than untreated 212 controls. On the other hand, 17-AAG induced the abundance of that complex (Fig. 4,  213 lower left panel). However, when expressed as the ratio of p53 to Hsp90, to reflect the 214 binding affinity of the components in the complex, neither LPS, nor 17-AAG exhibited 215 any effect. 216 vehicle or 1EU/ml LPS for 0.25 to 4 hours. LPS induced Ser166 phosphorylation of the 218 negative regulator of p53, MDM2, at each time point. Densitometric analysis of 219 immunoblots revealed that maximal increase in pMDM2 occurred after 1h exposure to 220 LPS (Fig. 5A, upper panel) . (Fig. 6B, 6C ) and S 392 (Fig 6D, 6E) , whereas 17-AAG 234 decreased p53 phosphorylation (Fig. 6A, B, C, D) . The maximal effect of LPS on p53 235 phosphorylation occurred at 0.25 hours (Fig. 6B, 6D ) or 2hours (Fig. 6C, E) . As shown 236 before, p53 expression levels were reduced by LPS and induced by 17-AAG (Fig. 6A (Fig 7B, 7C ,7D (Fig. 1E ). Furthermore, LPS was able to reduce the expression of p53 both 296 in vitro and in vivo and that effect was blocked by Hsp90 inhibitors. We have employed 297 two different Hsp90 inhibitors which represent two different generations of these 298 compounds. 17AAG is a geldanamycin derivative and it is the first Hsp90 inhibitor 299 selected by for clinical use; AUY922 is a isoxazole derivative which is now being 300 developed and is undergoing clinical trials in cancer patients(24). The key role of p53 in 301 cellular defense against inflammatory stimuli was further demonstrated in a study 302
showing that the activation of lung p53 by nutlin prevents and reverses pulmonary 303 hypertension and that hypoxia-exposed p21 null mice exhibit exacerbated pulmonary 304 hypertension compared to wild type (42). 305 p21, the direct downstream target of p53, is involved in the vascular defense against 307 pathogens. p21 null mice demonstrate an over-active inflammatory phenotype that is 308 similar to that of p53 null mice and display increased susceptibility to endotoxic shock 309 and increased serum levels of cytokines. Elevated NF-κB activity and secretion of 310 cytokines was detected in LPS-stimulated p21 deficient mice and in human 311 macrophages compared to similarly treated wild-type cells (55, 60). Our study shows 312 that LPS reduces p21 expression in vitro, an effect which probably contributes to the 313 LPS-induced endothelial barrier dysfunction. That effect was opposed by Hsp90 314 inhibitors (Fig. 2, Fig. 3) . 315
Furthermore, we show for the first time that Hsp90 forms a complex with p53 in 316 HLMVEC and that the abundance, but not the affinity, of that complex in the cellular 317 environment is influenced by both by LPS and 17-AAG (Fig. 4) . When HLMVECs were 318 treated with LPS the amount of the Hsp90-p53 complex was reduced and this may be 319 the cause of the lower p53 expression, as seen in Figure 2A . On the other hand, 17-320 AAG induced the formation of that complex which has been previously shown to 321 partially stabilize p53 (21, 64, 65) . 322
To further elucidate the mechanisms which regulate the p53 expression by LPS, 323 we treated HLMVEC with LPS for various time points and evaluated the phosphorylation 324 of the ubiquitin ligase MDM2, which plays a key role in the regulation of p53 stability by 325 serving as its major negative regulator (31). LPS, an AKT activator (41), can 326 significantly increase MDM2 phosphorylation, a post translational modification which is 327 crucial for p53 degradation (40). Akt-mediated phosphorylation of MDM2 at Ser166 and 328 Ser186 increases its interaction with p300, allowing MDM2-mediated ubiquitination and 329 degradation of p53 (22, 39, 69) . Phosphorylation of MDM2 also blocks its binding to 330 p19ARF, thus increasing the degradation of p53 (17, 69) . 331
To investigate the mechanisms by which 17-AAG induces p53 expression, we 332 pretreated HLMVEC with 17-AAG prior to LPS treatment. 17-AAG suppressed the LPS-333 induced MDM2 phosphorylation. LPS also induced the expression of the p53 negative 334 regulator MDMX (56) and this effect was opposed by 17-AAG pretreatment. p53 335 phosphorylation has been shown to regulate its activity (38) . In the present work we 336 evaluated the phosphorylation of p53 by LPS, since that post translational modification 337 has been shown to accelerate the degradation of p53 through the polyubiquitination -338 proteasome pathway (19). LPS induced p53 phosphorylation at Ser15 and Ser392. On 339 the other hand, 17-AAG suppressed both the basal p53 phosphorylation levels and the 340 LPS-induced p53 phosphorylation at both sites. We thus conclude that 17-AAG inhibits 341
Akt leading to reduced MDM2 phosphorylation, reduced p53 ubiquitination, degradation 342 and thus increased p53 survival. 343
The Rho family of GTPases regulates a wide variety of cellular processes, 344 including apoptosis, cell cycle progression and migration. Although this family of protein 345 is comprised of some 22 members, the best characterized are RhoA, RhoB, RhoC, 346
Rac1 and Cdc42 and most of them are involved in the regulation of endothelial barrier 347 function (7). RhoA is involved in the regulation of actomyosin contractility, cytokinesis, 348 focal adhesion and cell polarity and has been shown to be activated by LPS (54, 57) . In 349
the present study we demonstrate that p53 negatively regulates the LPS- 
